How Roche Engineers Antibodies to Target Two Different Diseases Simultaneously

A method for creating a custom-engineered antibody that can grab onto two different targets at once, designed to help the immune system fight complex diseases.

What it covers

This patent describes a way to build a bispecific antibody, which is a protein designed to bind to two different antigens (targets) instead of the usual one. It achieves this by swapping the internal building blocks of the antibody's light and heavy chains in one of the two pairs. To ensure these two different pairs connect correctly rather than creating a jumbled mess, the patent uses a 'knob-into-hole' strategy. By modifying the CH3 domains of the heavy chains—adding a bulky amino acid to one (the knob) and a smaller one to the other (the hole)—the antibody is forced to assemble in the exact, functional configuration required.

What it doesn't cover

• —Does not cover standard antibodies that only bind to a single type of antigen.
• —Does not cover bispecific antibodies that do not use the specific domain-swapped architecture defined in claim 1.
• —Does not cover methods of assembly that rely on techniques other than the described knob-into-hole CH3 domain modification.
• —Does not cover the specific therapeutic use or clinical application of the antibodies, only the structural composition and production method.

The clever bit

The innovation is the 'domain exchange' combined with the 'knob-into-hole' structural modification, which prevents the incorrect pairing of antibody chains that typically plagues the production of bispecific proteins.

Why it matters

Bispecific antibodies are a major focus in modern oncology because they can act as a bridge, bringing immune cells directly to tumor cells. By enabling a stable, bivalent, bispecific structure, this patent helps solve the manufacturing challenge of ensuring these complex molecules fold correctly, which is essential for developing reliable cancer immunotherapies.

Real-world examples

• 1.Bispecific T-cell engagers (BiTEs)
• 2.Cancer immunotherapy drug development
• 3.Roche's CrossMab technology platform